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Abstract
Following challenge with COPV (canine oral papillomavirus), DNA plasmids encoding COPV L1, E1 or E2 protein were delivered into
oral mucosal and cutaneous sites in beagles using particle-mediated immunotherapeutic delivery (PMID). Two weeks post-challenge, a
priming dose of 8 g DNA was delivered followed by a booster dose after a further two weeks. A group of control dogs were vaccinated
using plasmid DNA encoding Hepatitis B virus surface (HBVs) gene. All of the control animals developed warts at the vast majority of sites
(94%). All of the animals given wild type L1, E1, or E2 developed warts at most sites (88%, 75%, and 88%, respectively). The animals
given codon optimised E2 however, were protected from wart growth with only one tiny lesion seen on a single animal that persisted for
only a few days. The E1 codon optimised group was also significantly protected with a far lower number of smaller warts (48%) that
persisted for a shorter duration. These data suggest that therapeutic immunisation by PMID with papillomavirus early genes is effective and
emphasizes the importance of antigen load in the generation of protective responses to papillomavirus proteins.
© 2003 Elsevier Inc. All rights reserved.
Introduction
Papillomavirus has been closely associated with ano-
genital warts and cervical cancer for many years (zur
Hausen, 1976). These diseases are the most common STDs
in industrialized countries and affect 1 in 100 women per
annum, and as such, are very important in terms of both
morbidity and mortality (Birley, 2001). Some lesions re-
gress spontaneously, but others prove refractory to treat-
ment (Beutner and Ferenczy, 1997). Current anogenital
warts treatments are surgical in basis and do not prevent
recurrence, therefore, the development of a potential thera-
peutic vaccine is of great value and interest. Canine oral
papillomavirus (COPV) is a very good model of mucosal
HPVs causing morphologically very similar lesions to those
seen in mucosatropic anogenital HPV6 and 11 infections.
COPV induced lesions typically appear 4–8 weeks post-
challenge and follow an immune driven spontaneous regres-
sion over the next 6–8 weeks (Nicholls et al., 2001b). This
infection follows a tight time course and is highly repeatable
in our hands.
We have pursued this model for vaccine trials and have
previously shown the efficacy of prophylactic DNA vacci-
nation using COPV early genes (Moore et al., 2002), as well
as the major capsid L1 DNA (Stanley et al., 2001). We
wanted to know if early genes could impact on disease
progression when delivered after challenge with infectious
COPV and therefore mirror more closely a therapeutic vac-
cine. Previously, we have illustrated the impact on disease
by antigen load in a prophylactic vaccine (Moore et al.,
2002). This has been continued in the reported experiment
where we have compared directly wild type and codon
optimised early genes in a therapeutic regimen.
Previous therapeutic DNA vaccination studies have been
performed in the haired skin CRPV model. One study illus-
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trated significant impact on papilloma regression using a
combination of early genes (Han et al., 1999), but single
genes were less effective (van Driel et al., 1999). In the
mucosal BPV-4 model, the coat proteins L1 and L2 were
seen to have a minimal effect when delivered therapeuti-
cally (Campo, 1997; Campo et al., 1993), but E7 reduced
disease burden (Campo, 1997). Therapeutic human vaccines
have concentrated on late stage cancerous lesions and have
therefore focused on E6/E7 as a target antigen with limited
success. Several vaccine formulations have been trialed
including peptides, fusion proteins, recombinant viruses and
DNA vaccination (Borysiewicz et al., 1996; Klencke et al.,
2002; Muderspach et al., 2000; Ressing et al., 2000; Steller
et al., 1998; van Driel et al., 1999).
Results
The expression levels of the various plasmid vaccines
used were analysed in 293 cells. Fig. 1 and 2 illustrate the
increased expression seen with the codon optimised plas-
mids. In particular with E1 where no protein expression was
detectable from the wild type sequence, but the codon op-
timised E1 was readily detectable (Fig. 2) using the anti-
peptide antisera. The E2 codon optimised sequence showed
a marked increase in expression level from the wild type
sequence (Fig. 1). Due to the lack of a suitable antibody for
COPV E2 detection a his tag was added to the constructs for
E2 in vitro expression, allowing its easy detection using
anti-his antibodies (Fig. 1). Untagged constructs were used
for the in vivo vaccinations. Data is presented using 2
separate anti-his antibodies. The tetra-his antibody gave
higher background, but enabled the detection of wild type
E2 expression. The penta-his antibody gave a cleaner signal,
but the low level of wild type E2 was not detectable (Fig. 1).
In the control (HBVs) group of animals warts developed
at nearly every challenge site (94%) (Fig. 4) with a duration
and diameter (Fig. 3) similar to that seen in previous ex-
periments (Moore et al., 2002; Stanley et al., 2001). Sero-
conversion against L1 also followed a similar pattern to that
observed previously (Moore et al., 2002). This trend was
also followed for the wild type vaccines with the majority of
sites developing papillomas (75%) and these lesions being
of a similar size and duration. The E1 wild type vaccine may
have had a slight effect on disease burden but this was not
statistically significant. The animals vaccinated with the L1
vaccine that was protective when delivered prophylacti-
cally, developed warts at the vast majority of challenge sites
(88%) and were smaller at the early stages of disease (Fig.
3 and 4). This vaccine was expected to have a minimal
effect on disease burden when delivered therapeutically due
to its direction exclusively against the viral coat protein that
is only expressed very late in the viral life cycle (Nicholls et
al., 2001a). The codon optimised vaccines had a substantial
impact on disease burden by all measurements. Codon op-
timised E1 vaccinated animals developed warts at fewer
than 50% of challenge sites and were of far shorter duration
and smaller mean size (Fig. 3 and 4). The majority of codon
optimised E2 vaccinated animals were completely lesion
free (3/4), the only papilloma that developed was a single
small lesion that persisted for under 7 days (Fig. 3 and 4).
Statistical analysis of wart size
Statistical analysis of the mean wart diameter revealed
that E1 c/opt vaccinated animals developed significantly
smaller warts for shorter duration (p  0.001). Statistical
Fig. 1. Western blots of 293 cells transfected with plasmid constructs as
follows: (A) Vector Control. (B) pCOPV E2wt his tagged. (C) pCOPV E2
c/o his tagged. E2 protein detected by tetra (A) or penta (B) His antibody
(Clontech).
Fig. 2. Western blot of transfected 293 cells, antibody detection using anti
E1 peptide antisera. (A) His tagged COPV E1 positive control. (B) Vector
only control. (C) pCOPV E1wt. (D) pCOPV E1 c/o.
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analysis for the other vaccinated groups revealed little sig-
nificant differences in wart size as compared with the con-
trol group (HBVS), although there was some evidence of a
more rapid reduction in size. Analysis was not performed on
the E2 codon optimised group as only one tiny lesion was
observed at a single site.
DTH response
In order to determine if the vaccine could induce a cell
mediated response, a DTH measurement was taken using an
intra-dermal injection of recombinant adenovirus. Fig. 5
illustrates the mean resultant responses to E1 for each vac-
cination group. There was no significant response to the
control adenovirus, but a statistically significant (p  0.05)
induration was observed to the E1 adenovirus. This E1
induration was also observed in the control animals (HBVS
or L1 vaccinated) illustrating a cell mediated response to E1
in the course of a natural infection with COPV prior to
visible wart development. The starting ear thickness for
these animals fell within a range of 1.6–2 mm, therefore the
resultant ear swelling of approximately 0.8 mm equated to
an increase of 40–50%. The induration in the E1 vaccinated
animals were marginally larger than that observed in the
control animals (HBVS group), but this was not statistically
significant.
Discussion
This study demonstrates the efficacy of a therapeutic
single early gene DNA vaccine against COPV. The demand
for a therapeutic genital wart vaccine is great as current
treatments are unsatisfactory with many genital papilloma
lesions being refractory to treatment or recurrent (Birley,
2001). There is no adequate in vitro model of papilloma
development, so in order to study the efficacy of potential
vaccines, animal models are employed. Numerous mouse
models are used to determine immune response to potential
vaccines or to study anti-tumour responses, but these mod-
els cannot study the effect on wart growth or regression. A
few vaccine studies on the cotton tail rabbit papillomavirus
(CRPV) model have been undertaken including a therapeu-
tic DNA delivery of early genes (Selvakumar et al., 1995),
but this model is haired skin and not mucosal. Some early
work has been undertaken in a mucosal model in cattle
using BPV-4 (Campo et al., 1993), but this model has
husbandry problems and the lesions are in a difficult area to
study. The data presented here illustrates that codon opti-
mised early genes are effective vaccines when delivered
post-challenge in the mucosal COPV model. The short
period of spontaneous regression seen in the COPV life
cycle makes any potential therapeutic vaccine effect hard to
measure if delivered to mature warts. Therefore, the post-
challenge but pre-lesion lag phase (4–8 weeks) was utilised
to test therapeutic efficacy. This regime is also clinically
useful as any therapeutic effect would be relevant in the
many cases of HPV positive women without visible lesions
as well as helping to induce regression in those with existing
lesions. An early gene vaccine directed at all stages of the
viral life cycle (E1 or E2) could be used alone or in con-
junction with a prevention of entry prophylactic vaccine
directed at the viral coat (L1) creating a very powerful dual
function vaccine. We have previously shown that early
genes (E1) can work effectively as prophylactic vaccines
when delivered alone (Moore et al., 2002). This vaccine
could then induce regression of existing lesions, prevent
re-emergence and prevent re-infection.
From the data presented, both E1 and E2 are effective
therapeutic antigens in this system, but E2 has emerged as
a stronger candidate for further investigation providing vir-
tually complete protection in all animals vaccinated. L1 has
been shown to be an effective prophylactic vaccine in this
system (Stanley et al., 2001), but had little impact when
delivered therapeutically. This is not unexpected as the L1
protein is only expressed at a very late stage in the wart life
cycle and supports the theory of an L1 vaccine acting at a
prevention of entry level when delivered prophylactically.
Codon optimisation was critical to therapeutic vaccine
efficacy in this model. When wild type E1 and E2 were
used, little therapeutic effect was seen but the same vaccine
Fig. 4. Percentage of challenge sites developing warts.
Fig. 3. True mean wart size.
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had a dramatic impact when the codon optimised version
was used. This effect is probably due to an increased antigen
load resulting from the correct codon usage, but may also be
due to enhanced expression in certain cell types where the
tRNA and synthetase expression is more appropriate.
A further observation from the data is a measurable cell
mediated (DTH) response to the early protein E1 even
before the visible appearance of lesions. This response was
seen in the control and vaccinated groups and is compelling
evidence of a cell mediated immune response to E1 very
early in the wart life cycle. The slightly stronger DTH
response in the vaccinated groups as compared to the con-
trols implied an enhanced cell mediated response to E1 but
greater numbers would be required to determine if this
effect was real.
Materials and methods
Vaccination protocol
Five experimental vaccine groups, each comprising 4
beagles, were given pCOPVE1, pCOPVE2, pCOPVL1,
pCOPVE1c/o, or pCOPVE2c/o vaccines. The control group
was composed of 4 beagles vaccinated with pCOPVHBVs.
All dogs were challenged with COPV as previously de-
scribed (Stanley et al., 2001), then 2 weeks later, DNA
vaccines were delivered into the upper oral (lip) mucosa,
three sites on each side, and mid-ventral abdominal skin
(three sites on each adjacent side of the linea alba). Booster
vaccinations were delivered 2 weeks following primary
immunisation and performed in a similar manner. Each dog
received a total dose of 8 g DNA per session of immuni-
sation. Blood samples were taken prior to challenge and
every two weeks thereafter. Following viral challenge, de-
velopment of papillomas was monitored, measured, and
documented. Weekly mean papilloma size per beagle was
analysed using a mixed model analysis of variance upon all
groups besides E2 c/opt. Post-hoc comparisons were made
between HBVs and the other groups for each week using
Fisher’s LSD test with a confidence interval of 95%.
Delivery of plasmid vaccines and viral challenge were
performed on dogs under general anesthesia as previously
described (Stanley et al., 2001).
Expression vectors
The “experimental” DNA vaccines utilised in this study
were pCOPVL1, pCOPVE1c/o, pCOPVE1, pCOPVE2, and
pCOPVE2c/o plasmids that contained the complete open
reading frames of COPV L1, E1 codon optimised (for mam-
malian expression), COPV E1, E2, and E2 codon optimised
(for mammalian expression), respectively, cloned into a
CMV-promoter controlled plasmid expression vector
WRG7077 provided by PowderJect Vaccines, Inc., Madi-
son, WI, USA. The “control” DNA vaccine used was
pCOPVHBVs (PowderJect Vaccines, Inc., Madison, WI,
USA) containing the complete open reading frames of Hep-
atitis B surface antigen cloned likewise into WRG7077. The
L1 and early genes were derived directly from COPV ge-
nomes by PCR (Moore et al., 2002).
The COPV E2 open reading frame was codon optimised
in a similar manner to the COPV E1. The program Calcgene
(Hale and Thompson, 1998) was used to optimise the se-
quence so it contained codons that reflected those in highly
expressed mammalian genes. An overlapping olignucle-
otide (40 bases) approach was used to incorporate the
changes by PCR. Cloning was achieved by incorporating
Not1 and BamH1 sites into the gene and utilizing the ap-
propriate cloning site in the WRG7077 vector. This plasmid
was then denoted pCOPVE2c/o.
Delivery of these plasmids for vaccination was carried
out using the PowderJect XR device (PowderJect Vaccines,
Inc., Madison, WI, USA) at a delivery pressure of 400 psi
(Stanley et al., 2001). The preparation of cassettes for PMID
was as previously described in (Stanley et al., 2001).
Fig. 5. Ear swelling as a measure of E1 DTH.
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Viral challenge
Animals were subjected to general anesthesia and the
mucosa of the upper lips was lightly scarified using the tip
of a scalpel blade. Five sites per side of the upper lip were
scarified over an area of approximately 10 mm  10 mm
per site. An aliquot of 10 l of purified COPV suspension
(approximately 45 ng of COPV L1 protein), isolated and
characterised from a clinical case of oral papillomatosis
(Nicholls et al., 1999) was applied over each scarified site
using a pipette. The suspension was allowed to be absorbed
for about 3–5 minutes.
Serum collection
Blood samples were collected aseptically from either the
jugular vein in the neck or from the cephalic vein in the
forearm as previously described in (Stanley et al., 2001).
Ten to fifteen milliliters of blood was placed into a universal
tube containing 100 mg EDTA per milliliter of sample. The
tube was occasionally swirled to mix on transit to prevent
clotting. Following the centrifugation (Sorvall RC3B) of
blood samples at 2500 g for 10 minutes, serum was aspi-
rated, aliquoted, and frozen at 70°C for use in enzyme-
linked immunosorbent assay (ELISA).
Recombinant adenovirus production
Recombinant adenoviruses were made using the admid
system (Richards et al., 2000), provided by GSK. Briefly the
gene (E1/E2) was cloned into the multiple cloning site of
the admid transfer vector pCR259. This was followed by
transposition into the admid homing vector containing lac-
ZattTn7 site. Transposition into this site disrupts lac Z
reading frame, thus allowing for screening of recombinant
plasmids. Selected white colonies are retransformed into
DH10B competent cells to amplify and segregate the re-
combinant Ad plasmid that is then purified in large quanti-
ties, linearised by Pac 1 and transfected into HEK 293 cells.
Virus stocks thus obtained were propagated in HEK 293
cells, harvested after 7 days of infection and virus released
by freezing and thawing. Before use, the virus was titered
and purified on caesium chloride gradients.
Delayed type hypersensitivity response
A DTH response to E1 was measured using a recombi-
nant replication deficient adenovirus. Six days post-boost an
intradermal injection of 0.5 ml of PBS containing E1 ade-
novirus (1  105 pfu) was given to the right ear of each
animal and a similar injection was given to the left ear
containing control adenovirus (1  105 pfu). Ear swelling
after 48 h was measured using digital calipers.
In vitro expression
Vaccine constructs were transfected into 293 cells in
tandem with reporter GFP constructs in order to determine
efficiency. Cell lysates were then run on polyacrylamide
gels and western blotted. Antibody detection of COPV gene
products was either by an anti–his antibody (Clontech), for
detection of his tagged E2, or by anti-peptide antisera (for
E1).
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